Aloxi (Palonosetron Hydrochloride) - Summary

ALOXI SUMMARY

ALOXI^® (palonosetron HCl) injection for Intravenous

ALOXI¹ (palonosetron hydrochloride) is an antiemetic and antinauseant agent. It is a selective serotonin subtype 3 (5-HT₃) receptor antagonist with a strong binding affinity for this receptor.

ALOXI is indicated for:

1. the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, and
2. the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

ALOXI NEWS HIGHLIGHTS

Media Articles Related to Aloxi (Palonosetron)

Raloxifene Cuts Risk of Certain Type of Breast Cancer
Source: MedicineNet raloxifene Specialty [2008.06.12]

Raloxifene Safe for Women With Decreased Kidney Function
Source: MedicineNet raloxifene Specialty [2008.04.10]

FDA Okays Patch to Relieve Chemo-Induced Nausea and Vomiting
Source: MedPage Today Product Alert [2008.09.15]

Nausea and Vomiting
Source: MedicineNet Antiemetics Specialty [2008.04.29]

Research Evaluates Acupressure For Chemo Induced Nausea
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2008.09.24]

more>>

Published Studies Related to Aloxi (Palonosetron)

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. [2008.05.01]

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. [2008.03.07]

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. [2006.09]

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. [2005.09]

Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. [2005.05]

more>>

Clinical Trials Related to Aloxi (Palonosetron)

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI) [Recruiting]

Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab [Not yet recruiting]

Safety and Efficacy of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting [Completed]

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting [Recruiting]

Palonosetron, Aprepitant, and Low-Dose Dexamethasone in Preventing Nausea and Vomiting in Patients Undergoing High-Dose Chemotherapy and Stem Cell Transplant for Multiple Myeloma or Lymphoma [Recruiting]

more>>